Drug Trial Radar · NCT00054717
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
630
Actual
Start
Jan 2003
Primary completion
Sep 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 10, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
Conditions
- HIV Infections
Interventions
TipranavirDrug
Ritonavir(r)Drug
Comparator Protease Inhibitor (CPI)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Response at Week 48Time frame: At week 48
- Time to Treatment Failure Through 48 Weeks of TreatmentTime frame: Week 48
Locations
117 sites in 4 countries. Site status is shown where the registry gives one.
1182.12.62 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1182.12.108 El Rio SIA
Tucson, Arizona
1182.12.9 Boehringer Ingelheim Investigational Site
Berkeley, California
1182.12.23 Boehringer Ingelheim Investigational Site
Beverly Hills, California
1182.12.12 Boehringer Ingelheim Investigational Site
Fountain Valley, California
1182.12.76 Boehringer Ingelheim Investigational Site
Long Beach, California
1182.12.1 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.12.59 David Geffen School of Medicine at UCLA
Los Angeles, California
1182.12.82 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.12.97 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.12.69 UC Davis Medical Center
Sacramento, California
1182.12.89 Boehringer Ingelheim Investigational Site
San Diego, California
1182.12.99 Boehringer Ingelheim Investigational Site
San Diego, California
1182.12.25 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.12.5 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.12.53 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.12.98 University of Colorado Health Sciences Center
Denver, Colorado
1182.12.7 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
1182.12.103 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1182.12.52 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1182.12.70
Washington D.C., District of Columbia
1182.12.79 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
1182.12.77 Boehringer Ingelheim Investigational Site
Fort Myers, Florida
1182.12.45 Boehringer Ingelheim Investigational Site
Miami, Florida
1182.12.75 CARES Resource
Miami, Florida
1182.12.85 Boehringer Ingelheim Investigational Site
Miami, Florida
1182.12.93 Boehringer Ingelheim Investigational Site
Miami Beach, Florida
1182.12.17 Boehringer Ingelheim Investigational Site
Orlando, Florida
1182.12.90 Boehringer Ingelheim Investigational Site
Sarasota, Florida
1182.12.63 Boehringer Ingelheim Investigational Site
Tampa, Florida
1182.12.78 Boehringer Ingelheim Investigational Site
Tampa, Florida
1182.12.94 Infectious Disease Research Institute
Tampa, Florida
1182.12.67 Boehringer Ingelheim Investigational Site
Vero Beach, Florida
1182.12.123 Infectious Disease Clinics of Emory
Atlanta, Georgia
1182.12.88 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1182.12.72 Boehringer Ingelheim Investigational Site
Decatur, Georgia
1182.12.47 Boehringer Ingelheim Investigational Site
Macon, Georgia
1182.12.8 Family Practice Medical Center
Boise, Idaho
1182.12.105 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1182.12.3 Boehringer Ingelheim Investigational Site
Chicago, Illinois
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.